Menu
The speakers will briefly describe their experiences with negotiating PRV terms in license agreements, and how PRvs factor into their research programs.
The speakers will then delve into the nuts and bolts of some successful strategies each has used to negotiate reasonable and mutually acceptable revenue sharing terms for Priority Review Vouchers (PRVs) in agreements, particularly exclusive license agreements. We will also discuss ways of determining what each party contributed to the clinical development of the drug of interest that may be eligible for a PRV in the future and carefully thinking about “unique” market considerations such as extremely small patient populations, or disproportionally affects poor and marginalized populations.
Join us for a panel discussion examining approaches to technology partnering with global health organizations to widen market channels and increase access to medical products in underserved markets. The panel will discuss how funding and licensing collaborations between non-profit, multilateral, and industry partners can achieve meaningful and measurable improvements in equitable, global access, without diminishing commercial opportunities. You will hear practical guidance on access-oriented agreement terms, as well as real-world examples of implementing global access partnerships, and metrics for measuring their success beyond revenue generation.
Apple and Broadcom have filed an appeal to the Supreme Court of the Federal Circuit’s decision in the Apple v. CalTech case, which vacated a $1.1B verdict for CalTech, while confirming the validity of the relevant patents. Join our group of panelists in discussing the District Court and Federal Circuit opinions and the potential impact on patent value and strategy and other recent IP cases involving universities.
The panel will bring together speakers from a philanthropic venture fund/foundation, technology transfer office of an academic institution, a research and drug development company, and a private equity investment fund. The panel will explore the economic, scientific, social and even personal interests the parties have in funding and carrying out translational research. From funding of early stage research at an academic institution to drug development and commercialization at a biotechnology company, the panel will address the roles of funding from a disease-focused philanthropic venture fund and private equity investment. How transactions between the funders and research organizations can support drug development and also benefit the various stakeholders. The panel will consider successful strategies for structuring transactions between the parties that will lead to therapeutic development and optimal economic benefits for all.
University-industry collaboration is a powerful tool for leveraging resources and expertise to support innovative solutions to global issues and commerce. Maximizing the value of such collaborations, however, requires diligence and attention to manage and align the different perspectives and legal interest of the parties.
This session will provide a practical overview of the substantive legal issues, strategies, and common pitfalls around launching and managing successful university-industry collaborations via mechanisms that include startups, sponsored research, licensing, and industry consortia.
A panel of legal experts with complementary backgrounds will lead this discussion, casting a wide net around topics ranging from matching industry-university participants to scoping statements of work, managing information exchange, collaborating on intellectual property and licensing matters, and addressing financial terms and compliance.
Audience participation is encouraged, so come with your questions and war stories as this will be an interactive session!
Takeaways that will be highlighted include –
1. Harmonizing common sticking point deal terms with industry-university participants, policies and interests.
2. Aligning license and business terms to maximize commercial opportunities.
3. Practical approaches to address background and foreground IP rights.
4. Best practices to meet industry-university expectations and avoid breach.
5. Approaches for resolving disputes and potential for fallout.
Marc Maladro, Vice President at CZI, Mike Perham, Director of Innovations at HHMI’s Janelia Research campus, and Arden Yang from the Allen Institute in Seattle will discuss the increasingly important role that non-governmental funding plays in bioscience and computational research, how these institutions balance openness to collaboration and dissemination of basic science technologies, and other priorities to their institutes. Privately-funded institutes like these have more flexibility in their technology management and licensing programs, but also missions that may be unique to a founder’s vision. They also increasingly fund top researchers producing fundamental discoveries and technologies that spread through the non-profit and industrial scientific enterprise.
IUGI will do a deep-dive on the Deal of Distinction between the National Institutes of Health and uniQure N.V. Sector leadership will also provide updates on sector activities, discuss opportunities to get involved, and lead into sector networking.
Professional Conference Organiser